An observational study in Aortic Valve Stenosis, sponsored by Sahajanand Medical Technologies Limited. Recruiting at 4 sites in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Sahajanand Medical Technologies Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Aortic Valve Stenosis with a site in United Kingdom — 20 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · United Kingdom.
Among the 107 studies in Aortic Valve Stenosis with a site in United Kingdom, this one is the 32nd largest by planned enrollment of the 61 observational ones that give a count, is one of 9 that started in 2024, is one of 61 observational ones, reaches primary completion later than 21 of the 33 other live ones, and was the 100th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →20 of the 107 studies in Aortic Valve Stenosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Ceric Sàrl · Sites in United Kingdom, Austria, Estonia and 11 more countries
Ages 65–75
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 6–11
Imperial College London · Sites in United Kingdom
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 5
First in 2006; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 215 across the 46 interventional studies, 252 across the 61 observational. Of the 66 that completed or were terminated, 22 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 107 have an industry lead sponsor. The 10 most frequent:
Sahajanand Medical Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Sahajanand Medical Technologies Limited has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596460Barts & The London NHS TrustA Study to Obtain Imaging Data in 40 Patients Having Transcatheter Aortic Valve Implantation (TAVI) | 2026-12-12 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05758662St. Antonius HospitalThe Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) | 2027-06 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT06602609Imperial College LondonRemote Cardiovascular Monitoring in Post-TAVI Patients | 2027-07-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 107 studies in Aortic Valve Stenosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) using the Hydra transcatheter aortic heart valve (THV) series, in patients with severe aortic stenosis up to 1-year after the procedure. This will include an evaluation of the preservation of coronary access post implant by attempting to selectively engage both the right and left coronary arteries through standardised angiographic views.
The study will also examine the utility of 72 hours of post discharge remote ambulatory continuous electrocardiogram (ECG) monitoring using the novel Checkpoint Cardio System where it is clinically appropriate.
This is a prospective, observational, multi-centre study. The aim of this study is to collect clinical, procedural, and follow-up data in order to evaluate the efficacy and safety of the Hydra THV series (Vascular Innovations Co. Ltd., Nonthaburi, Thailand).
Additionally, the study will conduct the following evaluation:
Following discharge, clinical follow-ups are scheduled at 45 days (±14 days), and 1-year (±30 days).
Patient with severe aortic valve stenosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydra transcatheter aortic valve (THV) series
Device: Hydra transcatheter aortic valve (THV) series
The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
Primary safety endpoint
Early safety as defined by VARC-3 as composite of: * Freedom from all-cause mortality; * Freedom from all stroke; * Freedom from VARC 3 type 3-4 bleeding; * Freedom from major vascular, access-related, or cardiac structural complication; * Freedom from acute kidney injury stage 3 or 4; * Freedom from moderate or severe aortic regurgitation; * Freedom from new permanent pacemaker due to procedure-related conduction abnormalities; * Freedom from surgery or intervention related to the device.
Time frame: 45 days
Primary performance endpoint
Device success as defined by VARC-3 as composite of: * Technical success; * Freedom from mortality; * Freedom from surgery or intervention related to the device or to a major vascular or access related or cardiac structural complication; * Intended performance of the valve (mean gradient \<20mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation).
Time frame: 45 days
Technical success
As per VARC-3 defined criteria
Time frame: Immediately after the procedure
Cardiovascular mortality
Time frame: 45 days, and 1-year
All-cause mortality
Time frame: 45 days, and 1-year
All stroke
Time frame: 45 days, and 1-year
Disabling stroke
Time frame: 45 days, and 1-year
Myocardial infarction
Time frame: 45 days, and 1-year
Major vascular complication
Time frame: 45 days
Acute kidney injury
Time frame: 45 days
New permanent pacemaker implantation due to procedure related conduction abnormalities
Time frame: 45 days, and 1-year
New-onset atrial fibrillation
Time frame: 45 days, and 1-year
Coronary artery obstruction requiring intervention
Time frame: 45 days, and 1-year
Re-hospitalization for procedure- or valve-related causes
Time frame: 45 days, and 1-year
Mean aortic valve gradient
Time frame: 45 days, and 1-year
Effective Orifice Area (EOA)
Time frame: 45 days, and 1-year
Paravalvular leak
Time frame: 45 days, and 1-year
New York Heart Association (NYHA) functional class
Time frame: 45 days, and 1-year
Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Time frame: 45 days, and 1-year
Bioprosthetic Valve Failure (BVF), defined as valve-related mortality or aortic valve re-operation/re-intervention, or stage 3 haemodynamic severe structural valve deterioration
Time frame: 45 days, and 1-year
Bioprosthetic valve dysfunction (BVD), defined as structural valve deterioration, non-structural valve deterioration, clinical valve thrombosis, infective endocarditis
Time frame: 45 days, and 1-year
Stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies)
Time frame: 45 days, and 1-year
VARC-3 Type 3-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents used specifically for valve-related concerns (e.g., clinically apparent leaflet thrombosis)
Time frame: 45 days, and 1-year
Significant arrhythmias on rACM that would potentially lead to permanent pacemaker implantation (PPMI)
Time frame: 72 hours post hospital discharge
Ability to selectively engage and obtain diagnostic epicardial coronary angiography images from the right and left coronary ostia
Time frame: Immediately post-TAVI
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.
Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 36 months is close to that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahajanand Medical Technologies Limited